Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 430

1.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

N Engl J Med. 1999 May 27;340(21):1614-22.

2.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.

N Engl J Med. 1999 May 27;340(21):1605-13.

3.

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.

Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, Pomerantz RJ.

N Engl J Med. 1998 Dec 17;339(25):1803-9.

4.

Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy.

Izopet J, Salama G, Pasquier C, Sandres K, Marchou B, Massip P, Puel J.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):478-83.

PMID:
9859961
5.

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM.

N Engl J Med. 2001 Feb 15;344(7):472-80.

7.

Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.

Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L, Gerna G.

J Med Virol. 2001 Oct;65(2):207-17.

PMID:
11536225
8.

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.

Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML; French PRIMO Cohort Study Group (ANRS CO 06).

AIDS. 2006 Jan 9;20(2):159-70.

PMID:
16511408
9.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
10.

Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.

Andreoni M, Parisi SG, Sarmati L, Nicastri E, Ercoli L, Mancino G, Sotgiu G, Mannazzu M, Trevenzoli M, Tridente G, Concia E, Aceti A.

AIDS. 2000 Jan 7;14(1):23-9.

PMID:
10714564
11.

HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.

Re MC, Vitone F, Biagetti C, Schiavone P, Alessandrini F, Bon I, de Crignis E, Gibellini D.

Clin Microbiol Infect. 2010 Jun;16(6):640-6. doi: 10.1111/j.1469-0691.2009.02826.x. Epub 2009 Sep 2.

12.

Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.

Poggi C, Profizi N, Djediouane A, Chollet L, Hittinger G, Lafeuillade A.

AIDS. 1999 Jul 9;13(10):1213-20.

PMID:
10416525
13.

HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.

Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Delbeke E; "Apollo-97 Study".

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):154-7.

PMID:
11588509
14.

Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.

Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N.

AIDS. 1997 Jun;11(7):895-901.

PMID:
9189215
15.

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV.

PLoS One. 2009 Dec 31;4(12):e8490. doi: 10.1371/journal.pone.0008490.

16.

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.

Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C; Frnech PRIMO Cohort Study Group.

AIDS. 2001 Apr 13;15(6):665-73.

PMID:
11371680
17.

Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.

Vitone F, Gibellini D, Schiavone P, Re MC.

J Clin Virol. 2005 Jul;33(3):194-200. Epub 2004 Dec 15.

PMID:
15911440
18.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
19.

Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy.

Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD.

J Infect Dis. 2000 Feb;181(2):522-31.

20.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
Items per page

Supplemental Content

Write to the Help Desk